Manufactured in a facility that processes ingredients derived from milk (including lactose), soy, peanuts, other nuts, sesame seeds, cereals containing gluten, eggs, shellfish, and fish
Retina 2006
A number of other patents and patent applications contain prophetic disclosures of combination therapy where one agent is a melanocortin receptor agonist and a second agent is a PDE-5 inhibitor
Acknowledgements We thank Lauren Knightley, Beth Jago, Meirion Richards, and Amin Mirza of the Structural Chemistry team for their expertise and assistance, Swen Hoelder for his continuous support, Stephen Hearnshaw for his contributions to crystal optimisation, and Chris Richardson for crystallography computing support
Summary: GLP-1 receptor agonists may reduce inflammation by decreasing pro-inflammatory cytokines, modulating immune signalling pathways, and indirectly through weight loss and improved metabolic health